Showing results (41-50 of 196) with videos related to

Sort By:
Pageof 20
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2017
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationBartlomiej M Getta, Sean M Devlin, Ross L Levine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomasMaria E Arcila, Jamie E Chaft, Khedoudja Nafa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersBob T Li, Dara S Ross, Dara L Aisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila, Geoffrey R Oxnard, Khedoudja Nafa, et al.
The Journal of Molecular Diagnostics : JMD|December 28, 2019
Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array PlatformJamal K Benhamida, Jaclyn F Hechtman, Khedoudja Nafa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersHelena A Yu, Maria E Arcila, Natasha Rekhtman, et al.
Pageof 20